Results 231 to 240 of about 196,164 (338)

Tocilizumab and rituximab for systemic sclerosis interstitial lung disease: a real-world cohort analysis. [PDF]

Rheumatology (Oxford)
Goldman NR, Nihtyanova SI, Beesley CF, Wells AU, Denton CP, Renzoni EA, Mageed R, Ong VH.   +7 more
europepmc   +1 more source

Risk factors for silent cerebral infarction in immune‐mediated thrombotic thrombocytopenic survivors

British Journal of Haematology, EarlyView.
Summary Immune‐mediated thrombotic thrombocytopenic purpura (iTTP) survivors are predisposed to silent cerebral infarctions (SCI) defined as radiological evidence of brain ischaemia without focal symptoms. This study examined risk factors associated with SCI burden in iTTP survivors during remission.
Binish Javed, Jia Yu, Jenna Brown, Jay Meade, Gloria F. Gerber, Michael B. Streiff, Peggy Kraus, Samuel Merrill, Allyson M. Pishko, Jennifer Yui, Rakhi P. Naik, Robert A. Brodsky, Doris D. Lin, Shruti Chaturvedi   +13 more
wiley   +1 more source

Dosimetry and preclinical evaluation of long-term radiotoxicity following treatment with ²¹²Pb alpha-radioimmunotherapy targeting CD20. [PDF]

EJNMMI Res
Quelven I, Saidi A, Sage M, Mora-Ramirez E, Torgue J, Cogne M, Durand-Panteix S.   +6 more
europepmc   +1 more source

RITUXIMAB AS THE FIRST LINE OF TREATMENT IN EARLY DERMATOMYOSITIS – REPORT OF A PATIENT

Kardum, Željka, Frketić Mrović, Kristina, Tolić, Anela, Zekanović, Dražen   +3 more
openalex   +1 more source

Rituximab after Autologous Stem‐Cell Transplantation in Mantle‐Cell Lymphoma

New England Journal of Medicine, 2017
S. le Gouill, C. Thieblemont, L. Obéric, A. Moreau, K. Bouabdallah, C. Dartigeas, G. Damaj, T. Gastinne, V. Ribrag, P. Feugier, O. Casasnovas, H. Zerazhi, C. Haioun, H. Maisonneuve, R. Houot, F. Jardin, E. Van Den Neste, O. Tournilhac, K. Le Dû, F. Morschhauser, G. Cartron, L. Fornecker, D. Canioni, M. Callanan, M. Béné, G. Salles, H. Tilly, T. Lamy, R. Gressin, O. Hermine   +29 more
semanticscholar   +1 more source

The role of early immunotherapy in rasmussen's encephalitis. [PDF]

Neurol Sci
Ronne EJ, Khoshnood MM, Santoro JD.
europepmc   +1 more source

NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement

, 2007
Siao‐Yi Wang, Emilian Racila, Ronald P. Taylor, George J. Weiner   +3 more
openalex   +1 more source

Dynamics of circulating tumour DNA in relapsed/refractory diffuse large B‐cell lymphoma patients

British Journal of Haematology, EarlyView.
Summary The response to salvage chemotherapy in relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) is poor, and data on circulating tumour deoxyribonucleic acid (ctDNA) in this setting are limited. We evaluated ctDNA dynamics in 29 patients with relapsed or refractory DLBCL who received platinum‐based salvage chemotherapy at the University
Yujie Zhong, Johanna Bult, Nick Veltmaat, Filipe Montes de Jesus, Laurens Sillje, Joost Kluiver, Anke van den Berg, Wouter Plattel, Arjan Diepstra, Marcel Nijland   +9 more
wiley   +1 more source

Rituximab for Early-Onset Juvenile Dermatomyositis Complicated by Interstitial Lung Disease. [PDF]

Case Rep Pediatr
Olszewska M, Mężyk E, Kurbiel M, Kmiecik W, Turowska-Heydel D, Sobczyk M, Żuber Z.   +6 more
europepmc   +1 more source

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.

Journal of Clinical Oncology, 2010
C. Gisselbrecht, B. Glass, N. Mounier, Devinder Singh Gill, D. Linch, M. Trněný, A. Bosly, N. Ketterer, O. Shpilberg, H. Hagberg, D. Ma, J. Brière, C. Moskowitz, N. Schmitz   +13 more
semanticscholar   +1 more source